How big is the US market The rest of the world is covered
Ablatherm-HIFU is cleared for distribution in the European Union, South Korea, Canada, Australia, South Africa, New Zealand, the Philippines, Taiwan, Mexico, Argentina, Brazil and Russia. As of December 31, 2012, more than 32,000 prostate cancer treatments have been successfully performed in clinics outside the U.S. with Ablatherm-HIFU and results have been published in 60 peer-reviewed scientific publications.
tvman - According to cancer dot org, there will be 238,590 men in the US diagnosed w/prostate cancer in 2013. (Google "how many prostate cancer cases" and then go to American Cancer Society website). That sounds like a pretty sizable population of potential patients for EDAP.
Now, I don't know how many men will end up receiving ablation, but I would guess quite a few. If the choice were between surgery and ablation, I'm pretty sure I would choose abalation. I didn't look to find out what percentage of those diagnosed would be eligible for ablation. I suspect insurance companies would pay for ablation, especially since it will likely cost less than surgery. Any thoughts on that? Take care.